Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study

Michail Vikelis, Emmanouil V Dermitzakis, Konstantinos C Spingos, Georgios G Vasiliadis, George S Vlachos, Evaggelia Kararizou, Michail Vikelis, Emmanouil V Dermitzakis, Konstantinos C Spingos, Georgios G Vasiliadis, George S Vlachos, Evaggelia Kararizou

Abstract

Background: Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly® device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly® in a cohort of migraine patients previously refractory or intolerant to topiramate prophylaxis.

Methods: A prospective, multi-center clinical study was performed in patients diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician's suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® as the only preventive treatment.

Results: A small but statistically significant decline was shown over time in the number of days with headache (HA), the number of days with HA with intensity ≥5/10, and the number of days with use of acute medication after 3 months (p < 0.001 for all of the three changes). Twenty-three patients (65.7%) expressed their satisfaction and intent to continue treatment with Cefaly®. Compliance was higher among satisfied subjects compared to non-satisfied subjects. None of the explored factors were significantly associated with the reason for the failure of topiramate.

Conclusion: Three-months of preventive treatment for episodic or chronic migraine with t-SNS proved to be an effective, safe and well tolerated option for the treatment of patients with migraine who were intolerant or did not respond to topiramate.

Trial registration: ClinicalTrials NCT03125525 . Registered 21 April 2017.

Figures

Fig. 1
Fig. 1
Number of headache days (a,) number of headache days with intensity ≥5/10 (b) and number of days with acute medication use (c) by patient satisfaction over the 3-months active treatment period with Cefaly®
Fig. 2
Fig. 2
Number of days the device was not used by patient satisfaction over the 3-months active treatment period with Cefaly®

References

    1. Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global burden of disease study 2013. Lancet. 2015;386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4.
    1. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773–780. doi: 10.1111/j.1526-4610.2006.00437.x.
    1. Steiner TJ, Paemeleire K, Jensen R, et al. European principles of management of common headache disorders in primary care. J Headache Pain. 2007;8(Suppl 1):S3–47.
    1. Vikelis M, Dermitzakis E, Spingos K. et al. Greek Headache Society guidelines for the treatment of migraine. . Accessed 10 May 2017.
    1. Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia. 2015;35(1):51–62. doi: 10.1177/0333102414534325.
    1. Berger A, Bloudek LM, Varon SF, Oster G. Adherence with migraine prophylaxis in clinicalpractice. Pain Pract. 2012;12:541–549. doi: 10.1111/j.1533-2500.2012.00530.x.
    1. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.
    1. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952–970. doi: 10.1111/j.1468-1331.2007.01916.x.
    1. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16(2):157–168. doi: 10.1002/ana.410160202.
    1. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl 1):S44–S53. doi: 10.1016/j.pain.2013.07.021.
    1. Magis D, Sava S. D’ Elia TS et al. safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2313 headache sufferers in the general population. J Headache Pain. 2013;14:95. doi: 10.1186/1129-2377-14-95.
    1. Cefaly® Technology. . Accessed 11 May 2017.
    1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.
    1. Riederer F, Penning S, Schoenen J. Transcutaneous Supraorbital nerve stimulation (t-SNS) with the Cefaly® device for migraine prevention: a review of the available data. Pain Ther December 2015, Volume 4, Issue 2, pp 135–147.
    1. Linde M, Mulleners WM, Chronicle EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;24(6):CD010610.
    1. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697–704. doi: 10.1212/WNL.0b013e3182825055.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit